PHARMA-BIO SERV, INC.: 10-Q filed 2018-03-19
What PHARMA-BIO SERV, INC. reported in its quarterly report filed 2018-03-19 (fiscal Q1 2018): 34 published measures, 70 facts as tagged in accession 0001654954-18-002767.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-03-19
- Fiscal period
- fiscal Q1 2018
- Accession
- 0001654954-18-002767 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 22,409,436 | USD | |
| At 2017-10-31 | 22,350,001 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 4,240,996 | USD | |
| At 2017-10-31 | 1,602,715 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 18,168,440 | USD | |
| At 2017-10-31 | 20,747,286 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 13,176,240 | USD | |
| At 2017-10-31 | 11,751,714 | USD | |
| At 2017-01-31 | 13,670,616 | USD | |
| At 2016-10-31 | 13,773,582 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -2,664,012 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -382,135 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 1,481,848 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 185,391 | USD | 92 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 51,115 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 280,722 | USD | 92 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -16,945 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -7,800 | USD | 92 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -51,115 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -280,722 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 16,896,119 | USD | |
| At 2017-10-31 | 19,560,131 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 23,063,997 | shares | 92 |
| 2016-11-01 to 2017-01-31 | 23,051,349 | shares | 92 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 23,065,290 | shares | 92 |
| 2016-11-01 to 2017-01-31 | 23,088,560 | shares | 92 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -0.115 | USD/shares | 92 |
| 2016-11-01 to 2017-01-31 | -0.017 | USD/shares | 92 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -0.115 | USD/shares | 92 |
| 2016-11-01 to 2017-01-31 | -0.017 | USD/shares | 92 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 2,701,023 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 1,750 | USD | 92 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 2,291,912 | USD | |
| At 2017-10-31 | 2,390,545 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 17,550 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 22,050 | USD | 92 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 19,162 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -383,997 | USD | 92 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 19,694,344 | USD | |
| At 2017-10-31 | 19,536,531 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 1,484,599 | USD | |
| At 2017-10-31 | 1,542,920 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 6,053,081 | USD | |
| At 2017-10-31 | 7,208,054 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 13,659 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 1,882 | USD | 92 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 1,083,145 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 1,032,345 | USD | 92 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 1,063,983 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 1,416,342 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 23,062,531 | shares | |
| At 2017-10-31 | 23,089,631 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 218,946 | USD | |
| At 2017-10-31 | 137,671 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 2,443,077 | USD | |
| At 2017-10-31 | 2,293,329 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-01-31 | 423,180 | USD | |
| At 2017-10-31 | 422,925 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 37,011 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -380,385 | USD | 92 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -2,582,737 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -376,748 | USD | 92 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 149,748 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 109,460 | USD | 92 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 17,849 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 3,612 | USD | 92 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | 542 | USD | 92 |
| 2016-11-01 to 2017-01-31 | 635 | USD | 92 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-01-31 | -1,245,340 | USD | 92 |
| 2016-11-01 to 2017-01-31 | -849,170 | USD | 92 |
Inspect the source
- Entity
- PHARMA-BIO SERV, INC. / CIK 0001304161
- Captured
- 2026-09-19T11:17:27.241Z
- SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))